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Department of Therapy, Cardiology and Family Medicine 
 
Abstract. The article presents the results of a prevalence of hypertension (HT) among patients 
with gout and the role of laboratory markers of endothelial dysfunction in this group of patients. We 
examined 50 male patients with gout. HT was registered in 84% of patients, moreover the gout was 
preceded by HT in 52% of cases. The increase in the number of patients with chronic gout is due to 
the increase in the degree of HT. Significantly greater number of affected joints as well as an 
incidence of subcutaneous tophi and nephrolithiasis have been reported in patients with HT. In 
addition, these patients have poor adherence to antihypertensive treatment, as only 42% of patients 
with HT receive treatment. Significantly higher levels of C-reactive protein (CRP), ristocetin-induced 
platelet aggregation (RIPA), intima-media thickness (IMT) have been reported in patients with HT 
combined with gout in comparison with patients without gout, reflecting a significant breach of 
endothelial function. The increase in the number of cardiovascular cases in patients with gout leads to 
the increase of CRP, RIPA, IMT, it causes doctor‟s need to monitor these indicators. 
Keywords: hypertension, gout, endothelial dysfunction, laboratory markers, antihypertensive therapy. 
 
Introduction. HT is one of the most common diseases in the world. The prevalence of gout 
among patients with HT is about 30-40% [2]. It is believed that the defeat of the cardiovascular system 
occurs approximately in 50% of patients in the first 6-10 years after the debut of the gout [8]. Early 
development of inflammatory, metabolic disorders and endothelial dysfunction in patients with HT 
combined with gout in the early stages of the disease can lead to the development of atherosclerosis 
and coronary artery disease in these patients [7]. 
The main cause of death of patients with gout – cardiovascular complications such as HT – 74%, 
coronary artery disease – 17%, myocardial infarction – 14%, heart failure – 11%; stroke – 10% [1]. 
The actual problem is the use of reasonable pathogenesis of antihypertensive therapy in 
patients with HT combined with gout that will provide adequate control of blood pressure during the 
day. From a practical point of view an appointment of combination of two or more drugs is needed to 
control most patients‘ blood pressure [6]. 
Therefore, the aim of the study was to examine the prevalence of HT in patients with gout 
and the role of laboratory markers of endothelial dysfunction in these patients. 
Methods. We examined 50 male patients, whose average age was 54.5±5.6 years. Diagnosis 
of HT is set according to the criteria of the European Society of Cardiology and the European Society 
of Hypertension. The diagnosis of gout has been verified in accordance with the recommendations of 
the American College of Rheumatology and the European League Against Rheumatism 2015. 
Determination of CRP solid phase enzyme-linked immunoabsorbent assay (ELISA) was performed 
using reagents firm Dako (Denmark). Clinical and biochemical blood tests were performed using 
standardized methods. Determining the frequency of kidney damage in patients with gout was 
conducted on the results of the ultrasound of the kidneys. Evaluation of structural changes of the bone 
and surrounding tissue was performed using X-ray and ultrasonic methods. State of the common 
carotid artery (CCA) was estimated by the value of the intima-media thickness (IMT). In the control 
group included 30 healthy individuals representative of age and gender structure. Statistical analysis 
was performed using the application package STATISTICA 6.1. 
Results. HT was registered in 84% of patients, moreover the gout was preceded by the HT in 
52% of cases, the gout was previously diagnosed than HT in 48% of patients. First degree of HT was 
diagnosed in 10% of patients, 2 – in 30%, 3 – in 60%. The increase in the number of patients with 
chronic gout leads to the increase in the degree of HT. Average systolic blood pressure was 
148.2±12.0 (125 to 190) mm Hg, diastolic blood pressure – 97.3±10.0 (75 to 120) mm Hg. Depending 
on the presence or absence of HT patients were divided into two groups: I – patients with HT (84%), II 
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–  patients without HT (16%). It was found that significantly greater number of affected joints as well 
as the incidence of subcutaneous tophi and nephrolithiasis have been reported in patients with HT.  
In average duration of the gout was 6 years old. The average number of affected joints – 5. In the 
first 5 years of disease the medical aid was requested by 36% of patients, 64% of patients asked for it later. 
Average serum urate level indicator was 8.2 mg/dL. CRP ranged between 3.0-18.6 mg/L. There was a 
range of different severity disease (40% of patients had tophi). The frequency of flare (past 12 months) – 5-
26. Acute gouty arthritis was found in 4% of patients, chronic gouty arthritis – in 96% of patients. It has 
been studied a renal function in patients with gout. 26% of patients had nephrolithiasis, 14% – interstitial 
nephritis, 14% – chronic pyelonephritis, 20% – changes were detected. 
It was found a direct correlation between systolic blood pressure and age (r=0.16, p<0.05), the 
number of affected joints (r=0.37, p<0.05), disease duration (r=0.38, p <0.05). It was established 
statistically significant difference of concentration of uric acid in patients with HT and without it 
8.5±1.2 mg/dL and 7.8±1.6 mg/dL, respectively (p<0.05). 
The increasing of concentration of CRP more than 8.0 mg/L was observed in 32% of patients, 
it is combined with high hypercoagulable potential in 16%, determined by RIPA. It was established 
correlation between levels of CRP and clinical signs of the disease, the frequency of HT (r=0.33; 
p<0.01), metabolic syndrome (r=0.29; p<0.01), the presence of subcutaneous tophi (r=0.24, p<0.05), 
symptom «punched-out» (r=0.22; p<0.05). A direct correlation between CRP and RIPA with IMT 
(r=0.37; p<0.05) and (r=0.22; p<0.05), respectively. In addition, recent indicators correlated with 
certain risk factors for cardiovascular cases such as systolic blood pressure, total cholesterol, low-
density lipoprotein cholesterol, triglycerides. 
According to the study, patient‘s knowledge with gout about the availability of HT in a 
medical history was high – about 73% of patients. However, adherence to antihypertensive therapy 
was low, as only 42% of patients with HT were treated. According to the sociological survey of 
general practitioners (n=30) on the treatment strategy of patients with HT combined with gout it is 
often appointed main groups of antihypertensive drugs with proven first line hypouricemic action 
(losartan, amlodipine), if necessary – statins. This therapeutic tactics is not contrary to the 
recommendations of the European League Against Rheumatism (2016), which stated that when the 
HT it should be preferred losartan and calcium antagonists, with hyperlipidemia – statins and, if 
possible, it should be avoided thiazide diuretics. 
Conclusion. HT is a common disease in patients with gout, moreover the gout was preceded by 
HT. In addition, the course of gout with HT is heavier than those without HT. IMT significantly correlates 
with RIPA and with the level of CRP. The increase in CRP, RIPA, IMT leads to increase the risk of 
cardiovascular events in patients with gout, which causes doctor‘s need to monitor these indicators. 
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